ORIGIONAL ARTICLE

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score

Pedro Magalhães-Costa*, Luis Lebre, Paula Peixe, Sofia Santos, Cristina Chagas

Gastroenterology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal

Received 21 December 2015; accepted 9 February 2016
Available online 5 April 2016

KEYWORDS
Carcinoma, Hepatocellular; Hepatitis B, Chronic; Nucleotides; Risk Factors

Abstract

Objective: To investigate hepatocellular carcinoma (HCC) incidence, risk factors and the performance of baseline REACH-B risk score in a Portuguese chronic hepatitis B (CHB) population on antiviral therapy.

Methods: Retrospective study of CHB patients who were treated with tenofovir or entecavir for at least 12 months. Multivariate analysis was performed to identify factors associated with HCC. The Kaplan–Meier method was used to estimate the cumulative incidence of HCC at 1, 3 and 5 years on therapy. The performance of the REACH-B score at baseline was assessed.

Results: One hundred and twenty patients initiate nuclos(t)ide analogs (NUC) therapy (age, 47 ± 14 years-old; 83 male; 11% had cirrhosis; 71% tenofovir; 73% HBeAg-negative; 61% treatment-naive). After a median time under NUC of 39 months, 9 patients (7.5%) developed HCC. The calculated cumulative incidence rates of HCC at 1, 3 and 5 years on therapy were 5.1%, 7.3% and 8.8%, respectively. Independent predictors for HCC occurrence: age and cirrhosis at baseline. Diagnostic accuracy of baseline REACH-B score in predicting HCC development: AUC 0.738, 95%CI: 0.521–0.955. The cutoff value of 8 points had a sensitivity, specificity, positive predictive value and negative predictive value of 75%, 52%, 6% and 98%, respectively in predicting HCC occurrence during therapy.

Conclusions: Older age and cirrhosis at baseline were independent predictors for HCC development. Discriminatory performance of baseline REACH-B score was limited.
1. Introduction

It is believed that persistent viral replication together with the resulting liver injury are key risk factors for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).\(^1,2\) Additionally, important viral and host-related factors (genotype, HBV mutants, high HBV viral load, serum hepatitis B surface antigen [HBsAg] levels, older age, male gender, excessive alcohol intake and possibly metabolic syndrome) may affect the risk of HCC development.\(^3,5\) Long-term therapy with nucleos(t)ide analogs (NUC) has improved the overall outcome of chronic hepatitis B (CHB) and resulted in a significant reduction in the need for liver transplantation.\(^6\) Treatment with the third generation NUCs (entecavir and tenofovir) causes complete suppression of viral replication in more than 95% of the patients, with increased rates of hepatitis B e antigen (HBeAg) seroconversion (in HBeAg positive patients) and improved liver histology including reversal of histological cirrhosis in most cases.\(^7,11\) However, antiviral therapy reduces but does not eliminate the risk of HCC in CHB patients with or without cirrhosis. In fact, evidence of the effect of antiviral therapy on clinical outcomes including HCC related-incidence and mortality is weak, as demonstrated in a recent systematic review and meta-analysis.\(^12\) Most of the published data about the effect of NUCs on HCC risk are derived from older prospective cohort and case–control studies using lamivudine or interferon.

Regarding high-genetic barrier NUCs, most of the available data involve patients treated with entecavir (ETV), with initial reports regarding the effect of ETV being reported by Lamportico et al.\(^13\) This Italian study demonstrated that CHB patients with compensated cirrhosis and a persistently undetectable serum HBV DNA during 5 years of ETV monotherapy had an annual rate of HCC incidence of 2.5%, which is almost the same risk that had been reported in untreated HBeAg-negative European patients. Retrospective and prospective observational cohort studies that provide HCC data for CHB patients mainly treated with tenofovir disoproxil fumarate (TDF) are lacking. Until recently, the limited data on the risk of HCC following the treatment of CHB patients with TDF were obtained from the roll over study of registration trials in HBeAg-positive (GS-US-174-0103) and HBeAg-negative (GS-US-174-0102) patients.\(^14\) Buti et al. reported that the incidence of HCC in 152 patients with cirrhosis and 482 with CHB treated with TDF for 5 years was only 3.3% and 1.5%, respectively (annual incidence: 0.7%).\(^15\) Two recent studies,\(^14,16\) found that TDF reduced HCC incidence compared to the predicted HCC risk using the Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) calculator.

We performed a real-life single-center retrospective observational cohort study of 120 CHB Portuguese patients mainly treated with TDF. Univariate and multivariate analysis (Cox proportional hazards regression) of risk factors...
associated with HCC development were performed. Accuracy of a HCC-risk score (REACH-B) at baseline was assessed.\textsuperscript{17,18}

2. Patients and methods

2.1. Study population, clinical and laboratory evaluation

We included consecutive patients with CHB who were treated with tenofovir or entecavir for at least 12 months in Centro Hospitalar Lisboa Ocidental (Hospital Egas Moniz, Hospital Santa Cruz and Hospital São Francisco Xavier) – a tertiary referral center (catchment population \~993,000 individuals) – from January 2006 to February 2014. All patients had a positive HBsAg for at least 6 months. Exclusion criteria were as follows: less than 12 months on NUC therapy (n = 13), pre-existing HCC or HCC diagnosed within the first year of NUC therapy (n = 5), co-infection with hepatitis D virus, hepatitis C virus (n = 6) and/or human immunodeficiency virus (n = 6) – see Fig. 1 for flow-chart of study cases selection. Data were collected retrospectively from the medical records, either on paper or electronic charts. HBV DNA was measured by TaqMan (Roche Diagnostics) real-time polymerase chain reaction assay with a linear range of detection from 20 to 10\(^9\) IU/mL. Alanine aminotransferase (ALT) serum levels were measured biannually, normal range for our laboratory is between 21 and 72 U/L. Patients were retrospectively followed since CHB diagnosis until the end of follow-up or HCC occurrence (duration of follow-up) and since NUC therapy start until the end of follow-up or HCC occurrence (time on NUC therapy). Cirrhosis was defined by ultrasonographic findings (shrunken small liver with a nodular surface), clinical and laboratory findings compatible with portal hypertension (e.g., ascites, splenomegaly, gastroesophageal varices, thrombocytopenia). Cirrhotic and non-cirrhotic patients with clearly defined risk factors (such as, African patients over 20 year-old, Asian male patients over 40 years-old or female over 50 years-old, patients with family history of HCC) were followed by abdominal ultrasound and serum measurement of alfa-photoprotein every 6 months, as recommended by guidelines.\textsuperscript{19} Excessive alcohol intake was defined as a daily intake of \(>25\) g/alcohol. Total virological response was defined as undetectable HBV DNA at 3 or 6 months under antiviral therapy. Partial virological response was defined as a decrease in HBV DNA level of more than \(10\log_{10}\) IU/mL (but still detectable) after 6 months of therapy. Biochemical response was defined as normalization of ALT levels at any time during follow-up. The REACH-B score consists of five parameters: gender, age, ALT level, HBeAg status and HBV DNA level; it ranges from 0 to 17 points.\textsuperscript{17} After exclusion of baseline cirrhotic patients, REACH-B score was calculated at baseline, when patients began treatment. Cutoff values of 8 and 12 points were used to predict risks of HCC. The primary outcome of this study was HCC occurrence as defined by international societies guidelines.\textsuperscript{19} Approval for this study was obtained from our institutional ethics committee – Comissão de Ética para a Saúde, Centro Hospitalar de Lisboa Ocidental (complying with the Treaty of Helsinki). All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

2.2. Statistical analyses

Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, IL). Continuous variables are expressed as mean ± standard deviation or median (interquartile range) as appropriate. Qualitative and quantitative differences between subgroups were analyzed using \(\chi^2\) test or Fisher exact test for categorical parameters and Student \(t\) test or Mann–Whitney test for continuous parameters as appropriate. In order to achieve a comprehensive analysis, subgroup comparisons were performed. Univariate and multivariate analysis by Cox proportional hazards regression model was performed to identify factors associated with HCC. After univariate analysis, variables with a \(p < 0.05\) entered in the multivariate analysis. Effect sizes are expressed as hazard ratios (HRs), adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). The Kaplan–Meier method was used to estimate the cumulative incidence of HCC at 1, 3 and 5 years on therapy and differences between factors were evaluated by the log-rank test. To assess the performance of the cutoff values for REACH-B score at baseline, we used the receiver operating characteristic (ROC) curve. The sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value and negative predictive value of the different cutoff values for predicting HCC were estimated and reported. All statistical tests were two sided. Statistical significance was taken as \(p < 0.05\).

3. Results

3.1. Patients’ characteristics

A summary of baseline epidemiological, clinical and laboratory data of our cohort population is presented in Table 1. We identified 120 eligible CHB patients (mean age: \(47 \pm 14\) years-old; 83 male; 80 Caucasian; 32 HBeAg-positive). The median duration of follow-up and time on NUC therapy was 79 months (interquartile: 52–96) and 39...
Table 1  Subgroup comparison between non-cirrhotic versus cirrhotic CHB patients on antiviral therapy regarding baseline characteristics and HCC prevalence.

| Variable – n (%) | All patients | No-HCC | HCC | p | No-HCC | HCC | p |
|------------------|--------------|--------|-----|---|--------|-----|---|
| Number of patients | 120 | 103 | 4 | | 8 | 5 | |
| Gender – male | 83 (69) | 68 (66) | 3 (75) | 1.000 | 7 (88) | 5 (100) | 1.000 |
| Age – mean ± SD (y/o) | 47 ± 14 | 45 ± 14 | 63 ± 8 | 0.018 | 57 ± 10 | 65 ± 15 | 0.331 |
| – Age ≥ 50 y/o | 48 (40) | 34 (33) | 4 (100) | 0.015 | 6 (75) | 4 (80) | 1.000 |
| Duration of follow-up (mo) (median;IQR) | 79 (52;96) | 79 (52;96) | 80 (65;94) | 0.733 | 79 (42;219) | 79 (45;96) | 0.754 |
| Time on NUC therapy (mo) (median;IQR) | 39 (26;54) | 40 (26;55) | 34 (21;48) | 0.546 | 30 (25;33) | 46 (33;49) | 0.354 |
| Tenofovir | 85 (71) | 75 (73) | 2 (50) | | 5 (63) | 3 (60) | 1.000 |
| Entecavir | 35 (29) | 27 (26) | 2 (50) | 0.281 | 4 (50) | 2 (40) | 1.000 |
| Ethnic origin | | | | | | | |
| – Caucasian | 80 (67) | 68 (66) | 3 (75) | | 6 (75) | 3 (60) | |
| – African | 37 (31) | 32 (31) | 1 (25) | | 2 (25) | 2 (40) | 1.000 |
| – Asian | 2 (2) | 2 (2) | 0 (0) | 1.000 | 0 (0) | 0 (0) | 1.000 |
| – Other | 1 (1) | 1 (1) | 0 (0) | | 0 (0) | 0 (0) | |
| Excessive alcohol intake | 15 (13) | 8 (8) | 1 (25) | 0.280 | 3 (38) | 3 (60) | 0.592 |
| HBeAg positive (n = 115) | 32 (29) | 27 (26) | 0 (0) | 0.570 | 3 (38) | 2 (40) | 1.000 |
| HBV DNA baseline (log$_{10}$IU/mL) (median;IQR) | 1790 (400;189521) | 1578 (337;38458) | 15108 (526;43593) | 1.000 | 2551 (167;2595229) | 923450 (37025;2750000) | 0.683 |
| Cirrhosis at baseline | 13 (11) | N/A | N/A | N/A | N/A | N/A | N/A |
| REACH-B baseline (median;IQR) (n = 99) | 7 (5;9) | 7 (4;9) | 10 (8;14) | 0.109 | N/A | N/A | N/A |
| – ≥8 | 49 (50) | 46 (47) | 3 (75) | 0.071 | N/A | N/A | N/A |
| – ≥12 | 14 (14) | 12 (12) | 2 (50) | 0.004 | N/A | N/A | N/A |
| Previous antiviral treatment (n = 117) | 46 (39) | 42 (41) | 1 (25) | 0.639 | 2 (25) | 1 (20) | 1.000 |
| Virologic response (n = 117) | | | | | | | |
| – Total | 107 (92) | 92 (89) | 3 (75) | 0.316 | 7 (88) | 5 (100) | 1.000 |
| – Partial | 10 (8) | 8 (8) | 1 (25) | | 1 (13) | 0 (0) | |
| Biochemical response (n = 113) | | | | | | | |
| – Total | 109 (97) | 95 (92) | 3 (75) | 0.119 | 7 (88) | 4 (80) | 1.000 |
| HBeAg seroclearance/conversion (n = 27) | 9 (33) | 8 (30) | 0 (0) | 1.37 | 1 (37) | 0 (0) | |
| HBSAg seroclearance/conversion (n = 95) | 1 (1) | 1 (1) | 0 (0) | | 0 (0) | 0 (0) | |

Abbreviations: CHB, chronic hepatitis B; NUC, nucleos(t)ide analog therapy; HCC, hepatocellular carcinoma; SD, standard-deviation; y/o, years-old; mo, months; IQR, interquartile range; HBeAg, hepatitis B e antigen; N/A, non-applicable; HBSAg, hepatitis B surface antigen.

* After excluding patients with cirrhosis at baseline.
months (interquartile range: 26–54), respectively. A total of 13 patients (11%) had a baseline diagnosis of cirrhosis. Patients with cirrhosis were predominantly male ($p = 0.060$), older ($p = 0.002$) and had a higher prevalence of excessive alcohol intake ($p = 0.001$). Study samples (cirrhotic and non-cirrhotic) were matched regarding duration of follow-up, time on NUC therapy and chosen NUC, previous antiviral therapy, ethnic origin, HBeAg positivity, HBV DNA viral load at baseline, biochemical and virological response. The majority of our population was treated with tenofovir ($n = 85; 71$%). Seventy-one out of 117 (61%) of the patients were previously treatment-naïve. At the end of follow-up, 9 out of 27 (33%) HBeAg-positive patients had a serological response (HBeAg seroclearance/seroconversion) and one patient demonstrated HBsAg seroclearance/seroconversion.

3.2. Cumulative incidence of HCC

At a median treatment duration of 39 months (~3.3 years), nine patients (7.5%) developed HCC. A slight majority of patients (five out of nine patients; 56%) who developed HCC had underlying cirrhosis at baseline. The calculated cumulative incidence rates of HCC at 1, 3 and 5 years on NUC therapy were 5.1%, 7.3% and 8.8%, respectively, in the entire cohort. The cumulative incidence of HCC was significantly higher in patients with cirrhosis at baseline (Fig. 2). In the subgroup of patients without baseline cirrhosis, the cumulative incidence rates of HCC at 1, 3 and 5 years were 3.0%, 3.0% and 4.6%, respectively; in the subgroup of patients with baseline cirrhosis, the cumulative rates were 23.1%, 43% and 43%, respectively.

3.3. Factors associated with HCC development

Patients who developed HCC were older (64 ± 12 vs 46 ± 14; $p = 0.002$), had higher prevalence of excessive alcohol intake (44% vs 10%; $p = 0.015$), higher prevalence of cirrhosis at baseline (56% vs 7%; $p = 0.001$) and higher REACH-B scores at baseline (median 12 points vs 8 points; $p = 0.002$) (Table 1). On univariate analysis, age, excessive alcohol intake and cirrhosis at baseline were associated with subsequent development of HCC as seen in Table 2. On multivariate analysis, after adjusting for gender and time on NUC therapy, age (aHR: 1.085; 95%CI: 1.021–1.153; $p = 0.009$) and cirrhosis at baseline (aHR: 13.857; 95%CI: 1.105–20.734; $p = 0.036$) were independent predictors for HCC occurrence. Among the non-cirrhotic subgroup (Table 1), patients who developed HCC were older (63 ± 8 vs 45 ± 14; $p = 0.018$). On univariate and multivariate analysis (Table 2), age and a lack of biochemical response to antiviral therapy were associated with HCC occurrence. In the cirrhotic subgroup, there were no risk factors for HCC occurrence.

3.4. Performance of REACH-B HCC risk score at baseline

Table 3 and Fig. 3 show the AUC and diagnostic performance of baseline REACH-B score for HCC prediction among the non-cirrhotic population ($n = 107$). The AUC was 0.738 (95%CI: 0.521–0.955) for REACH-B score at baseline. At a cutoff value of 8 points, the REACH-B score had 75% sensitivity (three of four HCCs identified) and 51.6% specificity (49 of 95 patients without HCC classified in the low-risk group) to predict HCC during the follow-up period. In the subgroup of non-cirrhotic population previously treatment-naïve ($n = 58$), the obtained AUC was 0.615 (95%CI: 0.293–0.937).

4. Discussion

Chronic hepatitis B is a major cause of cirrhosis and hepatocellular carcinoma worldwide, being responsible for 1 million deaths per year. The risk of CHB progression to HCC, albeit not being totally eliminated, might be reduced by antiviral therapy; therefore, the identification and classification of patients who are at increased risk of developing HCC is important. Several HBV risk scores have been published so far. The REACH-B (Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B) score is
Table 2 Univariate and multivariate analysis of risk factors associated with HCC in CHB patients on antiviral therapy.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR, 95%CI           | p                     | aHR, 95%CI            | p         |
| **All patients**           |                     |                       |                       |
| Gender – male              | 3.351, 0.418–26.834 | 0.255                 |                       |           |
| Age ≥50 y/o                | 1.112, 1.049–1.180  | <0.001                | 1.085, 1.021–1.153    | 0.009     |
| Duration of follow-up      | 12.555, 1.569–100.456 | 0.017                |                       |           |
| Time on NUC therapy        | 0.975, 0.935–1.016  | 0.223                 |                       |           |
| Tenofovir                  | 1.880, 0.504–7.009  | 0.347                 |                       |           |
| Ethnic origin – Caucasian  | 0.930, 0.287–3.016  | 0.904                 |                       |           |
| Excessive alcohol intake   | 5.859, 1.572–21.836 | 0.008                 | 1.935, 0.420–8.918    | 0.397     |
| HBV DNA baseline           | 1.000, 1.000–1.000  | 0.613                 |                       |           |
| Cirrhosis at baseline      | 13.857, 3.541–54.225 | <0.001              | 4.787, 1.105–20.734   | 0.036     |
| Previous antiviral treatment | 0.411, 0.085–1.982 | 0.268                 |                       |           |
| Virologic response – total | 0.739, 0.092–5.912  | 0.775                 |                       |           |
| Biochemical response – total | 0.237, 0.029–1.941 | 0.180                 |                       |           |
| **No-cirrhosis**           |                     |                       |                       |
| Gender – male              | 1.440, 0.149–13.926 | 0.753                 |                       |           |
| Duration of follow-up      | 1.126, 1.023–1.239  | 0.015                 | 1.145, 1.028–1.277    | 0.014     |
| Time under NUC             | 0.999, 0.977–1.021  | 0.926                 |                       |           |
| Tenofovir                  | 0.963, 0.901–1.029  | 0.264                 |                       |           |
| Ethnic origin – Caucasian  | 2.686, 0.377–19.123 | 0.324                 |                       |           |
| Excessive alcohol intake   | 0.677, 0.085–5.364  | 0.712                 |                       |           |
| HBV DNA baseline           | 3.567, 0.370–34.414 | 0.271                 |                       |           |
| HBV DNA baseline           | 0.029, 0.000–268.931 | 0.447                |                       |           |
| REACH-B baselinea          | 1.314, 0.975–1.771  | 0.073                 |                       |           |
| • ≥8                       | 2.968, 0.308–28.588 | 0.346                 |                       |           |
| • ≥12                      | 6.655, 0.937–47.287 | 0.058                 |                       |           |
| Previous antiviral treatment | 0.457, 0.047–4.393 | 0.497                 |                       |           |
| Virologic response – total | 0.282, 0.029–2.723  | 0.274                 |                       |           |
| Biochemical response – total | 0.086, 0.009–0.836 | 0.034                 | 0.008, 0.000–0.686    | 0.034     |
| **Cirrhosis**              |                     |                       |                       |
| Gender – male              | 24.250, 0–7.3 × 10⁶ | 0.620                 |                       |           |
| Duration of follow-up      | 1.048, 0.968–1.136  | 0.249                 |                       |           |
| Time under NUC             | 0.990, 0.971–1.009  | 0.281                 |                       |           |
| Tenofovir                  | 1.003, 0.952–1.058  | 0.908                 |                       |           |
| Ethnic origin – Caucasian  | 0.814, 0.134–4.952  | 0.823                 |                       |           |
| Excessive alcohol intake   | 2.542, 0.404–15.997 | 0.320                 |                       |           |
| HBV DNA baseline           | 2.370, 0.391–14.366 | 0.348                 |                       |           |
| HBV DNA baseline           | 1.287, 0.213–7.758  | 0.783                 |                       |           |
| Previous antiviral treatment | 0.640, 0.071–5.775 | 0.691                 |                       |           |
| Virologic response – total | 24.250, 0–7.3 × 10⁶ | 0.620                 |                       |           |
| Biochemical response – total | 24.422, 0–2.6 × 10⁷ | 0.652                 |                       |           |

Abbreviations: HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; HR, hazard ratio; aHR, adjusted hazard ratio – adjusted for gender and time under NUC; CI, confidence interval; y/o, years-old; NUC, nucleos(t)ide analog therapy; HBeAg = Hepatitis B e antigen; a After excluding patients with cirrhosis at baseline.

A simple score, involving non-invasive parameters and has been externally validated. It is useful to assess the long-term risk of HCC development at 3, 5 and 10 years of follow-up. This risk-prediction score was derived from the community-based Taiwanese REVEAL-HBV study (a cohort of 3584 patients) without cirrhosis and no antiviral treatment. Later, Wong et al. demonstrated that REACH-B score maintained its predictive power in patients on antiviral therapy.

In the present study, we aimed to assess HCC incidence, risk factors and the performance of REACH-B in predicting HCC development in a Portuguese population (107 patients without cirrhosis) with CHB treated with NUCs (71% with
TDF). The estimated prevalence of this infection in the Portuguese population is approximately 1%, which is relatively low,\textsuperscript{24,25} however, there is no doubt that HCC incidence in Portugal is on the rise and its associated mortality and costs are high.\textsuperscript{18} In this retrospective cohort study, with a median time on NUC therapy of 39 months (\textpm 3.3 years), 9 out of 120 (7.5%) patients developed HCC, which is similar to the rate reported by Yang et al.\textsuperscript{26} Among patients without cirrhosis, four developed HCC (3.7%), which is similar to the rates reported by Wong et al.\textsuperscript{18} and, recently by Arend et al.\textsuperscript{30} The incidence and clinical presentation of HCC in CHB patients differs significantly by country and ethnic origin. In western countries, HBV related HCC is clearly associated with cirrhosis and excessive alcohol intake,\textsuperscript{21} whereas in Asia and sub-Saharan Africa, HCC can develop in carriers with mild liver fibrosis due to the long standing infection usually acquired at birth.\textsuperscript{31,32} Our findings corroborate data from Italy and Greece\textsuperscript{33,34} as on multivariate analysis, the independent predictors for HCC development despite NUC therapy were older age (aHR: 1.085; 95%CI: 1.021–1.153; \textit{p} = 0.009) and cirrhosis at baseline (aHR: 4.787; 95%CI: 1.105–20.734; \textit{p} = 0.036).

In the non-cirrhotic CHB patients of our study sample, multivariate analysis found that older age (aHR: 1.145; 95%CI: 1.028–1.277; \textit{p} = 0.014) and a lack of biochemical response to antiviral therapy (aHR: 124.046; 95%CI: 1.457–10559.174; \textit{p} = 0.034) were associated with HCC occurrence, which is supported by a very recent meta-analysis\textsuperscript{25} where age and the proportion of patients with elevated ALT levels predicted the incidence of HCC. Among the cirrhotic population there were no risk factors identified. This is evidence that age might be an important risk factor only in non-cirrhotic patients, whereas, cirrhosis itself is such a strong risk factor that it is seldom influenced by other co-factors (namely age) in the development of HCC. However, we cannot firmly conclude that because, as demonstrated in Table\textsuperscript{1}, our cirrhotic patients were significantly older at baseline than the non-cirrhotic cohort and due to small cirrhotic sample size (n = 13).

Using Kaplan–Meier method (Fig. 2) we observed that patients with cirrhosis at baseline had a significantly higher cumulative incidence of HCC (log-rank test <0.001). Despite not reaching statistical significance, similarly to Wong et al.,\textsuperscript{18} in our study, previous antiviral therapy conferred a modest protective effect (HR: 0.411; 95%CI 0.085–1.982; \textit{p} = 0.268) against HCC occurrence (Table 2).

The need for development of HCC risk scores is underlined by the knowledge that NUC therapy cannot completely eliminate the risk of HCC and that the identification of high risk patients might lead intensive HCC surveillance strategies and early detection of HCC and thus to a greater chance of curative treatment with improved survival.\textsuperscript{36} In our study, at a median time on therapy of 3.3 years, the baseline

| Table 3 | AUC and diagnostic performance of baseline REACH-B score for HCC in CHB patients on antiviral therapy. |
|---------|------------------------------------------------------------------------------------------------------------------|
| Cutoff  | AUC | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | LR+ | LR− | No. in high risk | No. in low risk | Correct prediction | Correct exclusion |
|---------|-----|----------------|----------------|--------|--------|------|------|----------------|----------------|-----------------|-----------------|
| AUC 0.738 | 95%CI: 0.521–0.955 | 95%CI: 95.9 | 50.0 | 79.3 | 8.3 | 81.7 | 14 | 85 | 1/4 | 49/95 |
| AUC 0.800 | 95%CI: 0.759–0.892 | 95%CI: 81.4 | 79.3 | 8.3 | 81.7 | 14 | 85 | 1/4 | 49/95 |
| AUC 0.800 | 95%CI: 0.759–0.892 | 95%CI: 81.4 | 79.3 | 8.3 | 81.7 | 14 | 85 | 1/4 | 49/95 |

Abbreviations: AUC, area under the ROC curve; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio.

\( ^{a} \) Includes treatment-naive and treatment-experienced patients.

---

**Figure 3** The AUC of REACH-B score at baseline to predict HCC.
REACH-B AUC obtained for prediction of HCC development (0.738; 95%CI: 0.521–0.955) was lower than the original and validation study of Yang et al.\textsuperscript{17} (AUC for predicting 3-year HCC risk of 0.811; 95%CI: 0.790–0.831) but similar to that obtained by Wong et al.\textsuperscript{18} (AUC for predicting 5-year HCC risk of 0.71; 95%CI: 0.62–0.81). The cutoff value of 8 points, yielded a sensitivity of 75%, specificity of 51.6%, positive predictive value of 6.1% and negative predictive value of 98%, which is similar to the results of the study by Wong et al.\textsuperscript{19} Also, in parallel with the aforementioned study, the performance of the baseline REACH-B risk score in our sub-group of previously treatment-naive patients was slightly inferior (Table 3). Our data highlights and confirms the major drawbacks of this risk score, which is its high false-positive rate, making it unable to correctly identify low-risk patients, as only 49 out of 95 patients without HCC were classified in the low-risk group. This might be due to the fact that, as in the original study, in our patients, cirrhosis was ruled out by ultrasound only. Another possible limitation of this risk score was described by Kim et al.\textsuperscript{14} Using a population mainly composed of TDF treated patients from the roll-over studies of registration trials, the real incidence of HCC and the incidence predicted based on the REACH-B score was evaluated. The authors found that after 3.3 years there was a progressive divergence between the predicted (by REACH-B score) and the observed number of HCC cases. Most studies addressing HCC occurrence during NUC therapy do not exceed 4–5 years, so it remains to be established if, with longer time on NUC therapy, HCC incidence remains stable. Hence, our data demonstrate that REACH-B score has many limitations especially in Caucasian populations, with AUC of 0.738, using Harrell’s c-index, it is considered as of modest diagnostic accuracy only. This considerably limits the utility of the score.

In clinical practice, patients at increased baseline HCC risk should continue to undergo regular HCC surveillance according to published guidelines,\textsuperscript{19} however, enhancing this recommendations with the addition of predictive risk scores (REACH-B) may identify additional patients at higher risk of developing HCC (REACH-B score at baseline ≥8 points) and who would thus benefit from HCC surveillance strategies. Accordingly, patients at higher risk for HCC, despite being on antiviral therapy, should undergo HCC surveillance. Notwithstanding, we must note that there is recent evidence demonstrating that a higher HCC detection might not lead to a reduced HCC-related mortality.\textsuperscript{25}

Another possible application for the REACH-B score could be the indication for antiviral treatment initiation, as shown in a recent study,\textsuperscript{37} where the authors demonstrated that the discriminatory performance of the REACH-B score in classifying antiviral treatment eligibility based on the local guideline (APASL 2012) was good/excellent with the exception of older HBeAg-positive patients.

Our study has some limitations, especially data regarding the cirrhotic cohort. It is evident that the cumulative incidence of HCC in cirrhotics was considerably high, exceeding most of previous reports of the South-European area (Italy, Greece, Spain), this is probably due to a small size of the sample. Also, most of the HCC cases in the cirrhotic cohort cumulate in the first months of therapy, suggesting a selection bias. The diagnosis of cirrhosis was based on clinical, laboratorial, radiological and endoscopic features (liver biopsy was not available for the non-cirrhotic population). Hence, patients with histological or early cirrhosis might have been unrecognized. Even with a long follow-up, due to a relatively small and rather heterogeneous cohort sample and the low number of events, our estimation of the accuracy of REACH-B risk score was limited. Another important limitation of our study is related to the fact that REACH-B score was originally derived from an Asian population. Additionally, HBsAg levels quantification, which is a novel marker, known by its high reproducibility and low cost, is currently not available in our institution. In fact, a link between HBsAg levels and HCC was first established by the ERADICATE-B cohort study.\textsuperscript{28} As a consequence, the original REACH-B risk calculator (known to underestimate the risk in patients with very low viral load at baseline) as suffered two major recent upgrades (using Asian cohorts only) in order to maximize its accuracy in predicting HCC occurrence. The most robust and costly REACH-B IIa, that incorporates the original factors plus HBV DNA and HBsAg levels quantification\textsuperscript{29} and the cheapest REACH-B IIb, which incorporates the original factors plus HBsAg levels quantification.\textsuperscript{30} Both upgraded risk calculators need further cost-effectiveness evaluation and external validation.\textsuperscript{3} The diagnosis of cirrhosis based on regular imaging and clinical parameters can be imprecise. Hence, recent developments in non-invasive tests of liver fibrosis may further improve the risk prediction. In fact, in a study performed by Lee and coworkers, the addition of liver stiffness measurement (by transient elastography) to REACH-B improved the diagnostic accuracy to predict liver-related events when compared to REACH-B score alone.\textsuperscript{39} Very recently, another risk score was developed by Papatheodoridis and coworkers in a large multicenter study in 1619 Caucasian European patients under NUC therapy (entecavir and tenofovir), the PAGE-B.\textsuperscript{40} The variables included in this risk score are: age, gender and platelet counts. This risk score appears to be very simple and probably the most suitable HCC risk predictor in Caucasian patients receiving antiviral therapy.

5. Conclusion

In conclusion, continued HCC surveillance is recommended for CHB patients on antiviral therapy. Age, excessive alcohol intake and cirrhosis remain as the most important risk factors associated with HCC onset in CHB patients on antiviral therapy. REACH-B score has many limitations, especially in Caucasian populations. With an AUC of 0.738 it is considered as of modest diagnostic accuracy and this considerably limits the utility of the score. This is the first study assessing the utility of the REACH-B HCC-risk score in Portugal. Prospective studies using larger samples, longer follow-up periods on antiviral treatment and the use of non-invasive measurement of liver stiffness will be particularly useful in order to clarify the best algorithm for HCC surveillance in CHB patients under nucleos(t)ide analogs therapy.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics
committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Authorship
Magalhães-Costa P, Lebre L and Chagas C. designed the research; Magalhães-Costa P. performed the research; Magalhães-Costa P. analyzed the data and performed the statistical analysis; Magalhães-Costa P. wrote the paper; Lebre L., Peixe P., Santos S. and Chagas C. critically revised the manuscript and approved the final version.

Conflicts of interest
The authors have no conflicts of interest to declare.

References
1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:535–50.
2. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:64–70.
3. Fattovich G, Borotolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–52.
4. Chen HP, Shieh JJ, Chang CC, Ten TT, Lin JT, Wu MS, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606–15.
5. Lin C-L, Tseng T-C, Kao J-H. What can we learn from hepatitis B virus clinical cohorts? Liver Int. 2015;35 Suppl. 1:91–9.
6. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680–6.
7. Chang TT, Lai KL, Kew Yoon S, Lee SS, Coelho HS, Carriho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.
8. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–93.
9. Liaw YF, Sheen IS, Lee CM, Akarca US, Papanicolaou DV, Su et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.
10. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.
11. Kritinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–42.
12. Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open. 2013;3. pii: e003265.
13. Lampertico P, Soffredini R, Viganò M. Entecavir treatment for NUC naive, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment. Hepatology. 2012;56:370A.
14. Kim WR, Berg T, Loomba R, Schall RA, Dinh P, Yee LJ, et al. Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol. 2013;58:519.
15. Buti M, Fung S, Gane E. Clinical, virological, serological and histological outcomes in cirrhotic patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 5 years. J Hepatol. 2012;56 Suppl. 2:197–8.
16. Coffin CS, Rezaeeavall M, Peng JX, Alcantara L, Klein P, Burak KW, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40:1262–9.
17. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–74.
18. Wong GLH, Chan HLY, Chan HY, Tse PCH, Tse YK, Mak CWH, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavit treatment. Gastroenterology. 2013;144:933–44.
19. Llovet JM, Ducrues M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JR, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
20. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–45.
21. Sung JY, Tsai KKF, Wong WVS, Li KCT, Chan HLY. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067–77.
22. Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology. 2005;48:23–8.
23. Yuen M-F, Tanaka Y, Fong DY-T, Fung J, Wong DK-H, Yuen JCY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–8.
24. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28:2437–44.
25. Wong WVS, Chan SL, Mo F, Chan TC, Loong HHF, Wong GLJH, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660–5.
26. Lecour H, Ribeiro AT, Amaral I, Rodrigues MA. Prevalence of viral hepatitis markers in the population of Portugal. Bull World Health Organ. 1984;62:743–7.
27. Santos A, Carvalho A, Tomaz J, Rodrigues V, Coxinho L, Bento D. Prevalência dos marcadores da infecção pelo vírus da hepatite B na população adulta do distrito de Coimbra. Acta Med Port. 2000;13:167–71.
28. Marinoto RT, Giria J, Moura MC. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993–2005). World J Gastroenterol. 2007;13:1522–7.
29. Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, et al. Virolological response to entecavit reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013;68:2154–63.
30. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64:1289-95.

31. Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756-63.

32. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000;92:1159-64.

33. Kew MC, Marcus R, Geddes EW. Some characteristics of Mozambican Shangaans with primary hepatocellular cancer. S Afr Med J. 1977;51:306-9.

34. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulos G, Raptopoulou-Gigi M, Gogos C, et al. Hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHB−) with or without cirrhosis treated with entecavir: results of the nationwide HepNet Greece cohort study. J Hepatol. 2013;58 Suppl. 1:S312.

35. Thiele M, Glud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses. PLOS ONE Public Libr Sci. 2014;9:e107177.

36. Wong GLH, Wong VWS, Tan GM, Ip KL, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79-87.

37. Chen TM, Chang CC, Huang PT, Wen CF, Lin CC. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Aliment Pharmacol Ther. 2013;37:243-51.

38. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-9.e3, quiz e13-4.

39. Lee MH, Yang HI, Liu J, Battria-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58:546-54.

40. Yang HI, Lee MH, Liu J, Chen CJ. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol. 2014;20:6244-51.